ACW Stock Overview
Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Actinogen Medical Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.025 |
| 52 Week High | AU$0.12 |
| 52 Week Low | AU$0.015 |
| Beta | 2.22 |
| 1 Month Change | 56.25% |
| 3 Month Change | 0% |
| 1 Year Change | -78.26% |
| 3 Year Change | 19.05% |
| 5 Year Change | -48.98% |
| Change since IPO | -96.95% |
Recent News & Updates
Recent updates
Is Actinogen Medical (ASX:ACW) In A Good Position To Invest In Growth?
Nov 16
Is Actinogen Medical (ASX:ACW) In A Good Position To Invest In Growth?
Aug 02We Think Actinogen Medical (ASX:ACW) Can Afford To Drive Business Growth
Apr 12We're Hopeful That Actinogen Medical (ASX:ACW) Will Use Its Cash Wisely
Nov 28Here's Why We're Not Too Worried About Actinogen Medical's (ASX:ACW) Cash Burn Situation
Aug 09Here's Why We're Not Too Worried About Actinogen Medical's (ASX:ACW) Cash Burn Situation
Apr 07We're Not Worried About Actinogen Medical's (ASX:ACW) Cash Burn
Oct 24Actinogen Medical (ASX:ACW) Is In A Strong Position To Grow Its Business
Jul 11We're Interested To See How Actinogen Medical (ASX:ACW) Uses Its Cash Hoard To Grow
Mar 27How Does Actinogen Medical's (ASX:ACW) CEO Pay Compare With Company Performance?
Jan 07
Shareholder Returns
| ACW | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | 13.6% | 2.1% | 0.5% |
| 1Y | -78.3% | -13.3% | -3.4% |
Return vs Industry: ACW underperformed the Australian Biotechs industry which returned -13.3% over the past year.
Return vs Market: ACW underperformed the Australian Market which returned -3.4% over the past year.
Price Volatility
| ACW volatility | |
|---|---|
| ACW Average Weekly Movement | 14.7% |
| Biotechs Industry Average Movement | 13.2% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in AU Market | 17.7% |
| 10% least volatile stocks in AU Market | 3.1% |
Stable Share Price: ACW is more volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 15% a week.
Volatility Over Time: ACW's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | n/a | Steve Gourlay | https://www.actinogen.com.au |
Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It is developing Xanamem, an inhibitor of the 11ß-HSD1 enzyme, which is in Phase 2 clinical trials that achieves target engagement in the central nervous system, depression with cognitive impairment, Alzheimer’s disease, and anxiety, sleep, and behavioral problems in fragile X syndrome. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015.
Actinogen Medical Limited Fundamentals Summary
| ACW fundamental statistics | |
|---|---|
| Market Cap | AU$56.35m |
| Earnings (TTM) | -AU$10.75m |
| Revenue (TTM) | AU$4.89m |
11.5x
P/S Ratio-5.2x
P/E RatioIs ACW overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ACW income statement (TTM) | |
|---|---|
| Revenue | AU$4.89m |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$4.89m |
| Other Expenses | AU$15.64m |
| Earnings | -AU$10.75m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0048 |
| Gross Margin | 100.00% |
| Net Profit Margin | -219.98% |
| Debt/Equity Ratio | 0% |
How did ACW perform over the long term?
See historical performance and comparison